X15695 effectively inhibited tumor growth over vehicle upon oral administration (30 mg/kg/day), albeit less effectively compared with enzalutamide (10 mg/kg/day; Fig. 8C and D), identifying X15695 as a weaker AR antagonist in this tumor model. This evidence concerns the gene AR and neoplasm.